加巴喷丁
非尔巴酸盐
拉莫三嗪
医学
不利影响
耐火材料(行星科学)
部分发作
抗惊厥药
安慰剂
临床试验
麻醉
癫痫
内科学
精神科
物理
病理
替代医学
天体生物学
出处
期刊:PubMed
日期:1994-06-01
卷期号:44 (6 Suppl 5): S23-2
被引量:25
摘要
The challenges of treating patients with partial seizures soon will be met, in part, by a number of new additions (felbamate, gabapentin, lamotrigine) to existing treatment options. Gabapentin, has shown significant promise in the treatment of patients with refractory partial seizures and secondarily generalized tonic-clonic seizures. Three large, randomized, multicenter, double-blind, placebo-controlled, parallel-group clinical trials have established its efficacy and safety as add-on therapy in patients with refractory partial seizures. Gabapentin is well tolerated. Although adverse events occur in most patients receiving gabapentin as adjunctive therapy, they are transient and mild to moderate in severity. To date, serious adverse events have been rare. Long-term safety data are needed. The lack of drug interaction potential between gabapentin and traditional antiepileptic drugs also was confirmed in clinical trials.
科研通智能强力驱动
Strongly Powered by AbleSci AI